-
Something wrong with this record ?
Long-Term Natural History of Microscopic Colitis: A Population-Based Cohort
J. Loreau, D. Duricova, C. Gower-Rousseau, G. Savoye, O. Ganry, H. Ben Khadhra, H. Sarter, C. Yzet, JP. Le Mouel, M. Kohut, F. Brazier, D. Chatelain, E. Nguyen-Khac, JL. Dupas, M. Fumery,
Language English Country United States
Document type Journal Article
NLK
Directory of Open Access Journals
from 2011
Free Medical Journals
from 2010
Freely Accessible Science Journals
from 2010
PubMed Central
from 2010
Europe PubMed Central
from 2010
Open Access Digital Library
from 2010-01-01
Open Access Digital Library
from 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2010
- MeSH
- Time Factors MeSH
- Adult MeSH
- Cohort Studies MeSH
- Colitis, Microscopic complications diagnosis therapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Prospective Studies MeSH
- Recurrence MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
OBJECTIVES: Data on long-term natural history of microscopic colitis (MC), including collagenous (CC) and lymphocytic colitis (LC), are lacking. METHODS: All new cases of MC diagnosed in the Somme area, France, between January 1, 2005, and December 31, 2007, were prospectively included. Colonic biopsies from all patients were reviewed by a group of 4 gastrointestinal pathologist experts to assess the diagnosis of CC or LC. Demographic and clinical data were retrospectively collected from diagnosis to February 28, 2017. RESULTS: One hundred thirty cases of MC, 87 CC and 43 LC, were included (median age at diagnosis: 70 [interquartile range, 61-77] and 48 [IQR, 40-61] years, respectively). The median follow-up was 9.6 years (7.6; 10.6). By the end of the follow-up, 37 patients (28%) relapsed after a median time of 3.9 years (1.2; 5.0) since diagnosis, without significant difference between CC and LC (30% vs 26%; P = 0.47). Twenty patients (15%) were hospitalized for a disease flare, and 32 patients (25%) presented another autoimmune disease. Budesonide was the most widely used treatment (n = 74, 59%), followed by 5-aminosalicylic acid (n = 31, 25%). The median duration of budesonide treatment was 92 days (70; 168), and no adverse event to budesonide was reported. Sixteen patients (22%) developed steroid dependency and 4 (5%) were corticoresistant. No difference in the risk of digestive and extradigestive cancer was observed compared with the general population. None of the death (n = 25) observed during the follow-up were linked to MC. In multivariate analysis, age at diagnosis (HR, 1.03; 95% confidence interval, 1.00-1.06; P = 0.02) and budesonide exposure (HR, 2.50; 95% confidence interval, 1.11-5.55; P = 0.03) were significantly associated with relapse. DISCUSSION: This population-based study showed that after diagnosis, two-third of the patients with MC observed long-term clinical remission. Age at diagnosis and budesonide exposure were associated with a risk of relapse.
Clinique Sainte Isabelle Abbeville France
Department of Pathology Amiens University Hospital Amiens France
Gastroenterology Unit Epimad Registry Amiens University Hospital Amiens France
Gastroenterology Unit Hôpital Charles Nicolle Rouen University Hospital Epimad Registry Rouen France
ISCARE 1 5 F a s IBD Clinical and Research Center Prague Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20025681
- 003
- CZ-PrNML
- 005
- 20201222155343.0
- 007
- ta
- 008
- 201125s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.14309/ctg.0000000000000071 $2 doi
- 035 __
- $a (PubMed)31478957
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Loreau, Julien $u Gastroenterology Unit, Epimad Registry, Amiens University Hospital, Amiens, France.
- 245 10
- $a Long-Term Natural History of Microscopic Colitis: A Population-Based Cohort / $c J. Loreau, D. Duricova, C. Gower-Rousseau, G. Savoye, O. Ganry, H. Ben Khadhra, H. Sarter, C. Yzet, JP. Le Mouel, M. Kohut, F. Brazier, D. Chatelain, E. Nguyen-Khac, JL. Dupas, M. Fumery,
- 520 9_
- $a OBJECTIVES: Data on long-term natural history of microscopic colitis (MC), including collagenous (CC) and lymphocytic colitis (LC), are lacking. METHODS: All new cases of MC diagnosed in the Somme area, France, between January 1, 2005, and December 31, 2007, were prospectively included. Colonic biopsies from all patients were reviewed by a group of 4 gastrointestinal pathologist experts to assess the diagnosis of CC or LC. Demographic and clinical data were retrospectively collected from diagnosis to February 28, 2017. RESULTS: One hundred thirty cases of MC, 87 CC and 43 LC, were included (median age at diagnosis: 70 [interquartile range, 61-77] and 48 [IQR, 40-61] years, respectively). The median follow-up was 9.6 years (7.6; 10.6). By the end of the follow-up, 37 patients (28%) relapsed after a median time of 3.9 years (1.2; 5.0) since diagnosis, without significant difference between CC and LC (30% vs 26%; P = 0.47). Twenty patients (15%) were hospitalized for a disease flare, and 32 patients (25%) presented another autoimmune disease. Budesonide was the most widely used treatment (n = 74, 59%), followed by 5-aminosalicylic acid (n = 31, 25%). The median duration of budesonide treatment was 92 days (70; 168), and no adverse event to budesonide was reported. Sixteen patients (22%) developed steroid dependency and 4 (5%) were corticoresistant. No difference in the risk of digestive and extradigestive cancer was observed compared with the general population. None of the death (n = 25) observed during the follow-up were linked to MC. In multivariate analysis, age at diagnosis (HR, 1.03; 95% confidence interval, 1.00-1.06; P = 0.02) and budesonide exposure (HR, 2.50; 95% confidence interval, 1.11-5.55; P = 0.03) were significantly associated with relapse. DISCUSSION: This population-based study showed that after diagnosis, two-third of the patients with MC observed long-term clinical remission. Age at diagnosis and budesonide exposure were associated with a risk of relapse.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a kohortové studie $7 D015331
- 650 _2
- $a kolitida mikroskopická $x komplikace $x diagnóza $x terapie $7 D046728
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a recidiva $7 D012008
- 650 _2
- $a časové faktory $7 D013997
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Duricova, Dana $u ISCARE I.V.F. a.s., IBD Clinical and Research Center, Prague, Czech Republic.
- 700 1_
- $a Gower-Rousseau, Corinne $u Lille University and Hospital, Public Health, Epidemiology and Economic Health, Registre Epimad, Maison Régionale de la Recherche Clinique, Lille, France. Lille University, Inserm, LIRIC Unit UMR 995 Team 5, Faculté de Médecine, Lille, France.
- 700 1_
- $a Savoye, Guillaume $u Gastroenterology Unit, Hôpital Charles Nicolle, Rouen University Hospital, Epimad, Registry, Rouen, France.
- 700 1_
- $a Ganry, Olivier $u Cancer Registry of the Somme-Inserm EA-DGS EA 4666 Epidemiology and Public Health Service, Amiens University Hospital, Amiens, France.
- 700 1_
- $a Ben Khadhra, Hajer $u Cancer Registry of the Somme-Inserm EA-DGS EA 4666 Epidemiology and Public Health Service, Amiens University Hospital, Amiens, France.
- 700 1_
- $a Sarter, Hélène $u Lille University and Hospital, Public Health, Epidemiology and Economic Health, Registre Epimad, Maison Régionale de la Recherche Clinique, Lille, France. Lille University, Inserm, LIRIC Unit UMR 995 Team 5, Faculté de Médecine, Lille, France.
- 700 1_
- $a Yzet, Clara $u Gastroenterology Unit, Epimad Registry, Amiens University Hospital, Amiens, France.
- 700 1_
- $a Le Mouel, Jean-Philippe $u Gastroenterology Unit, Epimad Registry, Amiens University Hospital, Amiens, France.
- 700 1_
- $a Kohut, Mathieu $u Clinique Sainte Isabelle, Abbeville, France.
- 700 1_
- $a Brazier, Franck $u Gastroenterology Unit, Epimad Registry, Amiens University Hospital, Amiens, France.
- 700 1_
- $a Chatelain, Denis $u Department of Pathology, Amiens University Hospital, Amiens, France.
- 700 1_
- $a Nguyen-Khac, Eric $u Gastroenterology Unit, Epimad Registry, Amiens University Hospital, Amiens, France.
- 700 1_
- $a Dupas, Jean-Louis $u Gastroenterology Unit, Epimad Registry, Amiens University Hospital, Amiens, France.
- 700 1_
- $a Fumery, Mathurin $u Gastroenterology Unit, Epimad Registry, Amiens University Hospital, Amiens, France.
- 773 0_
- $w MED00194310 $t Clinical and translational gastroenterology $x 2155-384X $g Roč. 10, č. 9 (2019), s. e00071
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31478957 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201222155338 $b ABA008
- 999 __
- $a ok $b bmc $g 1599826 $s 1116367
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 10 $c 9 $d e00071 $e - $i 2155-384X $m Clinical and translational gastroenterology $n Clin Transl Gastroenterol $x MED00194310
- LZP __
- $a Pubmed-20201125